Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor?

E K Schneider, Felisa Reyes-Ortega, Jian Li, Tony Velkov

Research output: Contribution to journalReview ArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question remains: Is this breakthrough combination therapy the “magic-bullet” cure for the vast majority of patients with CF? This review covers the contemporary clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights the emerging issues from recent conflicting literature reports.

Original languageEnglish
Pages (from-to)130-141
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume101
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Cite this

Schneider, E K ; Reyes-Ortega, Felisa ; Li, Jian ; Velkov, Tony. / Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor?. In: Clinical Pharmacology and Therapeutics. 2017 ; Vol. 101, No. 1. pp. 130-141.
@article{9931bb9f1e824444aefb1414fece03f1,
title = "Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor?",
abstract = "Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question remains: Is this breakthrough combination therapy the “magic-bullet” cure for the vast majority of patients with CF? This review covers the contemporary clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights the emerging issues from recent conflicting literature reports.",
author = "Schneider, {E K} and Felisa Reyes-Ortega and Jian Li and Tony Velkov",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cpt.548",
language = "English",
volume = "101",
pages = "130--141",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "American Society for Clinical Pharmacology and Therapeutics",
number = "1",

}

Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor? / Schneider, E K; Reyes-Ortega, Felisa; Li, Jian; Velkov, Tony.

In: Clinical Pharmacology and Therapeutics, Vol. 101, No. 1, 01.01.2017, p. 130-141.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor?

AU - Schneider, E K

AU - Reyes-Ortega, Felisa

AU - Li, Jian

AU - Velkov, Tony

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question remains: Is this breakthrough combination therapy the “magic-bullet” cure for the vast majority of patients with CF? This review covers the contemporary clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights the emerging issues from recent conflicting literature reports.

AB - Cystic fibrosis (CF) is a life-limiting disease caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) activity. The recent US Food and Drug Administration (FDA) approval of lumacaftor combined with ivacaftor (Orkambi) targets patients with the F508del-CFTR. The question remains: Is this breakthrough combination therapy the “magic-bullet” cure for the vast majority of patients with CF? This review covers the contemporary clinical and scientific knowledge-base for lumacaftor/ivacaftor and highlights the emerging issues from recent conflicting literature reports.

UR - http://www.scopus.com/inward/record.url?scp=85006036356&partnerID=8YFLogxK

U2 - 10.1002/cpt.548

DO - 10.1002/cpt.548

M3 - Review Article

VL - 101

SP - 130

EP - 141

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -